Search clinical trials for: Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]

Total 181 results

Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Influenza

Kazakhstan
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza

United States
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Influenza A Virus, H7N9 Subtype

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
Hualan Biological Bacterin Co. Ltd.

Completed

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

GCP

China
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Seasonal Influenza

China
Hualan Biological Engineering, Inc.

Completed

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Human Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

Influenza, Human

Finland, Italy, Germany
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

Influenza

Taiwan
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China

Influenza

China
National Institute of Allergy and Infectious Diseases...

Terminated

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Influenza | Influenza Immunisation

United States
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
University of Oxford

Completed

Swine Flu (Novel Influenza A H1N1) Vaccine Study

Influenza

United Kingdom
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Influenza, Human

China
BioNTech SE
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

Influenza

China
Emory University
Makerere University

Completed

Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda

Acquired Immunodeficiency Syndrome | HIV | Influenza

Uganda
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Orthomyxovirus Infections

Finland
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

Influenza

China
Solvay Pharmaceuticals

Completed

Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years

Healthy
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
International Vaccine Institute

Not yet recruiting

Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. (ECOVA-01)

COVID-19 Disease
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
Hualan Biological Bacterin Co. Ltd.

Completed

Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

GCP

China
CureVac

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Rabies

Belgium, Germany
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Laboratorios Liomont
EPIC Research CRO; ILS Clinical Research; Q Square Solutions

Completed

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Influenza, Human

Mexico
Opera CRO, a TIGERMED Group Company

Completed

Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects

Influenza

Italy
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
British Columbia Centre for Disease Control

Completed

Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity (TITRE)

Influenza

Canada

3

Subscribe